Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

electroCore, Inc. ECOR

Healthcare — Medical Devices
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.11
Total sells
0.95
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — 1 — — — — 1 — — 1 —
Sell — 1 1 — — — 2 2 — — 1 —
Insider Ownership
35.56%

Capital & Financial Ratios

Market Cap
102.60
Revenue
36.97
Net Income
(14.77)
Free Cash Flow
(9.74)
Net Debt
(4.28)
Current Ratio
1.21
Debt/Equity
(2.07)
P/E ratio
0.00
P/S ratio
2.97
P/B ratio
0.00
Past 5Y EPS Growth
41.43%
This Y EPS Growth
16.61%
Next Y EPS Growth
54.76%
Next 5Y EPS Growth
68.82%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 10.58 12.22 11.61 10.04
Receivables 0.72 1.37 1.03 0.91
Inventory 2.16 1.68 1.63 2.42
Other — — — —
14.29 16.30 15.67 14.12
2023 2024 2025 Q'26
Payables 2.16 1.83 2.71 2.18
ST’ Debt — — — —
Other — — — —
8.12 9.15 11.35 11.67
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 9.58 9.45 — —
—
’25 6.72 7.38 8.69 9.24
32.03
’24 5.44 6.14 6.55 7.05
25.18
’23 2.78 3.55 4.51 5.19
16.03
’22 1.90 2.16 1.98 2.56
8.59
’21 1.20 1.27 1.49 1.49
5.45
’20 0.73 0.75 1.08 0.93
3.50
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (3.01) (3.52) — —
—
’25 (4.35) (0.62) (1.67) (1.54)
(8.19)
’24 (2.56) (1.77) (1.36) (1.25)
(6.95)
’23 (5.86) (3.31) (2.37) (3.12)
(14.67)
’22 (4.78) (3.24) (4.61) (4.01)
(16.64)
’21 (4.16) (1.67) (3.45) (4.35)
(13.63)
’20 (8.49) (4.02) (3.96) (3.58)
(20.05)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (3.01) (3.52) — —
—
’25 (4.39) (0.65) (1.67) (1.54)
(8.25)
’24 (2.56) (1.77) (1.36) (1.25)
(6.95)
’23 (5.86) (3.40) (2.45) (3.16)
(14.87)
’22 (4.78) (3.24) (4.61) (4.01)
(16.64)
’21 (4.16) (1.67) (3.45) (4.35)
(13.63)
’20 (8.49) (4.02) (3.96) (3.58)
(20.05)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.59) (0.33) — —
—
’25 (0.47) (0.44) (0.40) (0.34)
(1.65)
’24 (0.53) (0.38) (0.31) (0.40)
(1.59)
’23 (1.24) (1.03) (0.68) (0.61)
(3.42)
’22 (1.20) (1.20) (1.20) (1.22)
(4.69)
’21 (1.65) (0.90) (0.90) (1.05)
(4.35)
’20 (4.05) (1.95) (1.50) (2.10)
(9.00)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ 2.93 3.10 5.32 4.16 — — —
Low Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 14.70 7.50 17.89 19.49 — — —
High Price
— ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 62 68 73 83 — — —
Employees
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.14 0.24 0.34 0.39 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.59 16.03 25.18 32.03 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 81.19% 82.51% 84.97% 86.75% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (22.59) (19.02) (11.98) (13.96) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (262.95%) (118.65%) (47.57%) (43.59%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (22.16) (18.83) (11.89) (13.97) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.55 0.96 0.76 0.64 — — —
Depreciation
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.82 2.91 3.37 3.78 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.69) (3.42) (1.59) (1.65) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.52) (2.66) (0.93) (0.97) — — —
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 (0.04) 0.00 (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.52) (2.70) (0.93) (0.97) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.61 1.35 1.01 (0.20) — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.73 5.52 7.48 8.48 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.20 2.05 4.82 1.19 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.10 4.42 16.08 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.19 1.43 4.36 1.04 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.10) (1.55) (15.34) (4.02) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.64) (14.67) (6.95) (8.19) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — — — (0.21) — (0.07) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.64) (14.87) (6.95) (8.25) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.13 6.17 7.15 4.32 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.70 — — 6.61 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.26) (10.58) (12.22) (5.00) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.09 7.44 7.54 (1.71) — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (65.58%) (92.19%) (65.00%) (71.37%) ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (82.49%) (153.57%) (158.63%) (478.70%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

ElectroCore (ECOR), a trailblazer in non-invasive vagus nerve stimulation through its gammaCore platform for migraines and cluster headaches, has delivered explosive revenue growth—from $254,100 in 2016 to $25.18 million in 2024, a nearly 9,800% surge—despite macroeconomic headwinds like inflation and supply chain woes. This momentum, propelled by FDA clearances, pandemic-driven demand, and efficiencies like gross margins expanding to 85%, has revenue per employee skyrocketing 2,620% to $344,959 with minimal headcount growth. Yet, the stock languishes near lows after a post-IPO crash from $303 highs, creating a stark disconnect as forecasts eye $56 million by 2027.

Narrowing losses tell a turnaround tale: EBT improved 79% to just -$12 million in 2024, with breakeven eyed for 2026 amid operating cash flow gains and a cash-positive balance sheet. Insider confidence shines through aggressive net buying by the CEO and directors (7:1 value ratio), aligning with gammaCore Sapphire’s prescription boom and pipeline potential in atrial fibrillation. Valuation metrics scream undervaluation—PS at 4.8x on 57% CAGR growth—versus peers.

Analysts project 120-460% upside, fueled by U.S. migraine market penetration and macro tailwinds like rate cuts sparking medtech M&A. While risks like dilution and reimbursement linger, ECOR’s operational leverage and insider bets position it as a high-conviction multibagger in a consolidating sector. Dive into the full analysis for the charts, correlations, and Q1 2026 catalysts.

Read full commentary →

electroCore, Inc. (ECOR) Latest News

News by impact score

Fine-tune

9 Sep

3 , 8:00 AM
electroCore, Inc. appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers. Co-CEO appointments may moderately affect strategic direction and market sentiment.

2 Sep

3 transcript www.marketbeat.com, 11:03 AM
Ecora Resources released H1 earnings call highlights covering financial results and operations. Earnings call highlights provide performance updates that can moderately sway near-term investor sentiment.

6 Aug

3 www.marketbeat.com, 9:03 PM
electroCore, Inc. (ECOR) Q2 earnings call highlighted revenue figures, operational updates, and growth strategies in neuromodulation therapies. Q2 earnings details typically deliver financial metrics that moderately shape near-term investor views on ECOR without major strategic shifts.

3 , 4:05 PM
electroCore, Inc. announced its second quarter 2026 financial results. Quarterly earnings releases typically produce moderate short-term share price movement without fundamentally shifting long-term strategy or competitive position.

16 Jul

3 , 8:00 AM
A new review analyzes anatomical and methodological differences between auricular and cervical vagus nerve stimulation techniques. Review advances understanding of vagus nerve stimulation methods central to electroCore technology.

9 Jun

3 GlobeNewswire, 8:00 AM
Frontiers in Neuroscience accepts review article synthesizing evidence that cervical nVNS activates the vagus nerve without surgery for electroCore, Inc. (ECOR). Review article acceptance adds scientific credibility to ECOR non-invasive vagus nerve stimulation but lacks immediate commercial or regulatory impact.

19 May

3 www.marketbeat.com, 3:02 AM
electroCore projects 30% growth and spotlights VA opportunities in its LD Micro Conference presentation. Growth outlook and VA channel updates may lift near-term sentiment and revenue visibility without altering core trajectory.

13 May

4 GlobeNewswire, 8:00 AM
electroCore announced publication in JAMA demonstrating benefits of adding Quell electrical nerve stimulation to outpatient physical therapy for fibromyalgia patients. JAMA publication provides high-impact clinical validation for Quell's efficacy in fibromyalgia, likely enhancing market adoption and investor sentiment.

7 May

4 transcript www.fool.com, 10:15 AM
electroCore, Inc. (ECOR) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, management commentary, and forward guidance. Q1 2026 earnings transcript discloses financial metrics, strategic initiatives, and outlook that significantly shape investor expectations and stock trajectory.

4 app.moby.co, 8:30 AM
electroCore, Inc. (ECOR) released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 earnings call summary discloses financial performance and strategic outlook capable of significantly swaying investor sentiment and stock trajectory.

6 May

4 transcript www.fool.com, 6:40 PM
electroCore (ECOR) released Q1 2026 earnings call transcript detailing quarterly financial results, revenue growth, operational updates, and forward guidance. Q1 2026 earnings transcript discloses key financial metrics, strategic initiatives, and outlook capable of significantly shifting ECOR's investor sentiment and trajectory.

4 GlobeNewswire, 4:05 PM
electroCore, Inc. (ECOR) announced first quarter 2026 financial results. Quarterly earnings announcements significantly influence financial performance and investor sentiment.

3 www.marketbeat.com, 8:07 PM
electroCore's Q1 earnings call highlighted financial results, including revenue growth, operational updates on gammaCore products, pipeline progress, and reaffirmed full-year guidance amid expanding commercial efforts. Q1 earnings highlights show moderate financial and operational influences balanced by ongoing commercialization challenges.

3 Zacks, 6:30 PM
electroCore, Inc. (ECOR) reported a first-quarter loss but beat revenue estimates. Q1 revenue beat despite loss moderately boosts short-term investor sentiment and highlights improving financial traction.

7 Apr

3 GlobeNewswire, 8:00 AM
electroCore announced first patient enrollment in an investigator-led clinical study evaluating gammaCore nVNS for PTSD treatment. Enrollment initiation expands gammaCore into PTSD, a new indication with potential to influence clinical pipeline and investor interest.

1 Apr

4 GlobeNewswire, 8:00 AM
electroCore, Inc. (ECOR) announced publication in Frontiers in Neuroscience demonstrating benefits of non-invasive vagus nerve stimulation (nVNS) using gammaCore in patients with mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD), showing improvements in sleep, mood, and PTSD symptoms. Publication provides clinical validation for nVNS in mTBI and PTSD, potentially expanding indications, enhancing credibility, and driving stock performance.

30 Mar

4 GlobeNewswire, 8:00 AM
electroCore, Inc. (ECOR) expands its intellectual property portfolio, strengthening protections for its innovations in non-invasive vagus nerve stimulation technology. IP portfolio expansion represents a major strategic move that bolsters competitive positioning and safeguards future revenue streams.

26 Mar

3 www.marketbeat.com, 11:08 AM
Ecora Resources shared highlights from their H2 earnings call, covering financial performance, operational updates, and strategic outlook. H2 earnings call highlights provide insights into financial results and operations, moderately influencing performance and investor sentiment.

23 Mar

4 GuruFocus.com, 9:01 PM
electroCore Inc (ECOR) reported record revenue in Q4 2025 earnings call, driven by strategic growth including expanded commercial efforts, gammaCore sales momentum, and new market opportunities. Record revenue and strategic growth directly boost financial trajectory and investor confidence.

19 Mar

4 transcript www.fool.com, 7:37 PM
electroCore (ECOR) Q4 2025 earnings call transcript details fourth-quarter financial results, revenue growth, operational updates, and forward-looking guidance from management. Q4 earnings transcript discloses key financial metrics and strategic plans with potential to significantly sway investor sentiment and stock trajectory.

4 www.marketbeat.com, 5:53 PM
electroCore, Inc. (ECOR) released highlights from its Q4 earnings call, covering financial results, operational updates, and forward guidance. Q4 earnings highlights disclose financial performance, revenue growth, and strategic initiatives that could significantly shape investor sentiment and stock trajectory.

4 GlobeNewswire, 4:05 PM
electroCore, Inc. (ECOR) announced full year 2025 financial results and organizational changes. Full-year financial results directly impact stock valuation and investor confidence, amplified by organizational changes signaling strategic shifts.

3 app.moby.co, 8:12 PM
electroCore, Inc. issued Q4 2025 earnings call summary detailing financial results, revenue growth, operational updates, and forward guidance amid expanding gammaCore adoption. Q4 earnings summary reveals financial performance and strategic outlook with moderate potential to influence investor sentiment and trajectory.

3 Zacks, 5:45 PM
electroCore, Inc. (ECOR) reported a Q4 net loss of $5.5 million, or $0.53 per share, wider than the prior year's $3.4 million loss, with revenue of $4.3 million missing Wall Street estimates of $5.1 million. Q4 loss widened and revenue missed estimates, impacting financial performance and short-term investor sentiment moderately.

4 Mar

3 , 10:00 AM
electroCore, Inc. (ECOR) may report negative earnings in its upcoming Q4 release, with analysis of key performance trends to monitor beforehand. Expected negative Q4 earnings will moderately affect ECOR's financial performance and investor sentiment ahead of the release.

21 Jan

3 GlobeNewswire, 8:00 AM
Acacia Clinics and the Vagus Nerve Society are conducting a study using electroCore’s gammaCore Sapphire device as an adjunctive treatment for symptoms associated with Post-Traumatic Stress Disorder (PTSD). This research aims to explore the efficacy of non-invasive vagus nerve stimulation in alleviating PTSD symptoms, potentially expanding the therapeutic applications of gammaCore technology. The study could moderately influence electroCore's market position by validating the use of its technology in a new therapeutic area.

20 Jan

4 GlobeNewswireMT NewswiresBarchartMT Newswires, 8:00 AM
electroCore, Inc. (ECOR) has provided a preliminary business update for the full year 2025, projecting approximately 26% revenue growth, estimating revenues between $31.8 million and $32.0 million. This growth reflects the company's ongoing efforts to expand its market presence and enhance its product offerings. The projected revenue growth indicates significant positive momentum for the company's future performance and market positioning.

24 Dec

3 Simply Wall St.Simply Wall St., 6:32 AM
Analysts predict that electroCore, Inc. (NASDAQ: ECOR) will reach breakeven soon, driven by expectations of improved financial performance and market conditions. The company's innovative approaches and product developments are seen as key factors in achieving this milestone, which could positively influence investor sentiment and market positioning. Expectations of reaching breakeven indicate a moderately noticeable influence on financial performance and market sentiment.

2 Dec

4 , 8:00 AM
electroCore, Inc. announced that its TAC-STIM device has shown significant performance improvements in active-duty United States Air Force airmen. The device, which utilizes non-invasive vagus nerve stimulation, aims to enhance cognitive function and reduce stress among military personnel. Initial results indicate that TAC-STIM may lead to better operational readiness and mental resilience, potentially benefiting airmen in high-pressure environments. This development aligns with the company's mission to advance neuromodulation therapies for various conditions. The successful demonstration of TAC-STIM's effectiveness in a military setting could significantly enhance electroCore's market position and drive future growth.

5 Nov

3 Zacks, 6:35 PM
electroCore, Inc. (ECOR) reported a loss for Q3 but exceeded revenue estimates. The company continues to focus on its non-invasive vagus nerve stimulation technology, which is aimed at treating various conditions. Despite the loss, the revenue performance indicates potential growth and interest in its products. Exceeding revenue estimates suggests moderate positive momentum, but the reported loss indicates ongoing challenges.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us